[go: up one dir, main page]

PE20001022A1 - Compuestos de pirazina - Google Patents

Compuestos de pirazina

Info

Publication number
PE20001022A1
PE20001022A1 PE1999000868A PE00086899A PE20001022A1 PE 20001022 A1 PE20001022 A1 PE 20001022A1 PE 1999000868 A PE1999000868 A PE 1999000868A PE 00086899 A PE00086899 A PE 00086899A PE 20001022 A1 PE20001022 A1 PE 20001022A1
Authority
PE
Peru
Prior art keywords
disorders
pirazine
compounds
alkyl
refers
Prior art date
Application number
PE1999000868A
Other languages
English (en)
Inventor
Brian Cox
Mark Patrick Healy
Deborah Wild
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20001022A1 publication Critical patent/PE20001022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRAZINA DE FORMULA I, DONDE R1 ES FENILO SUSTITUIDO POR HALOGENO DE PREFERENCIA TRICLOROFENILO; R2 ES NH2; R3 ES NH2, H; R4 ES CXNRaRb, CXNH-(CH2)y-NRaRb; X ES =O, =S; y ES 0-2; Ra Y Rb SON H, ALQUILO C1-C4 O JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS CON 1-2 N OPCIONALMENTE SUSTITUIDOS CON UNO O MAS ALQUILO C1-C4. UN COMPUESTO PREFERIDO ES 2,6-DIAMINO-5-CARBOXAMIDO-3-(2,3,5-TRICLOROFENIL)PIRAZINA. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION. EL COMPUESTO I ES UN BLOQUEADOR DEL CANAL DE SODIO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE EPILEPSIA, TRASTORNO BIPOLAR, DEPRESION MANIACA, DEPRESION UNIPOLAR, DOLOR, TRASTORNOS EN LA FUNCION DEL INTESTINO, TRASTORNOS NEURODEGENERATIVOS, NEUROPROTECCION, NEURODEGENERACION, ZUMBIDO DEL OIDO; TOLERANCIA INVERSA, UN AGENTE INDUCTOR DE DEPENDENCIA
PE1999000868A 1998-08-28 1999-08-26 Compuestos de pirazina PE20001022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818881.6A GB9818881D0 (en) 1998-08-28 1998-08-28 Compounds

Publications (1)

Publication Number Publication Date
PE20001022A1 true PE20001022A1 (es) 2000-10-16

Family

ID=10838055

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000868A PE20001022A1 (es) 1998-08-28 1999-08-26 Compuestos de pirazina

Country Status (15)

Country Link
US (2) US6503909B1 (es)
EP (1) EP1107960A1 (es)
JP (1) JP2002523499A (es)
KR (1) KR20010079696A (es)
CN (1) CN1324349A (es)
AU (1) AU5624999A (es)
BR (1) BR9913183A (es)
CA (1) CA2341543A1 (es)
CO (1) CO5130006A1 (es)
GB (1) GB9818881D0 (es)
MA (1) MA26681A1 (es)
PE (1) PE20001022A1 (es)
TR (1) TR200100603T2 (es)
TW (1) TW429255B (es)
WO (1) WO2000012488A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1255740T3 (da) 2000-02-16 2006-02-06 Neurogen Corp Substituerede arylpyraziner
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
GB0010971D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Process
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004018437A1 (en) 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
EA015166B1 (ru) * 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
WO2005095613A1 (ja) * 2004-03-30 2005-10-13 Genomidea Inc. Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
US20250188059A1 (en) * 2022-03-16 2025-06-12 Arum Therapeutics Inc Novel compound and use thereof for inhibiting checkpoint kinase 2
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575975A (en) 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3544568A (en) * 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.

Also Published As

Publication number Publication date
US6503909B1 (en) 2003-01-07
CA2341543A1 (en) 2000-03-09
CO5130006A1 (es) 2002-02-27
CN1324349A (zh) 2001-11-28
TW429255B (en) 2001-04-11
TR200100603T2 (tr) 2001-07-23
MA26681A1 (fr) 2004-12-20
EP1107960A1 (en) 2001-06-20
JP2002523499A (ja) 2002-07-30
US20030022904A1 (en) 2003-01-30
WO2000012488A1 (en) 2000-03-09
GB9818881D0 (en) 1998-10-21
KR20010079696A (ko) 2001-08-22
AU5624999A (en) 2000-03-21
BR9913183A (pt) 2001-05-15

Similar Documents

Publication Publication Date Title
PE20001022A1 (es) Compuestos de pirazina
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
PT1132403E (pt) Peptidos inibidores de tgf g beta1
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
PE20010647A1 (es) Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
BR0013626A (pt) Escova oral, corpo de escova oral, e, processos para produzir um corpo de escova oral, e para produzir uma escova oral
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
DE69936848D1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
ATE172460T1 (de) 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
DE60016393D1 (de) Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
TW200508180A (en) Therapeutic agents
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
NO2005015I2 (no) Terapeutisk aktiv forbindelse preparat inneholdende forbindelsen samt den anvendelse
AR019626A1 (es) Antagonistas receptores y5 de neuropeptidos.
PE20001037A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
IL169316A (en) Small molecules modulate hepatocyte growth factor (dispersion factor)
AR033426A1 (es) Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento
BR9909617A (pt) Composição farmacêutica
AR029428A1 (es) DERIVADOS DE FENIL--PIPERIDINA, TETRAHIDROPIRIDINA,-PIPERAZINA,-AZEPAN,-TETRAHIDRO-1H-AZEPINA Y DIAZEPAN SUSTITUIDOS, UNA COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA PREPARACION FARMACEUTICA
PE120099A1 (es) Nueva 3,4-diariltiazolina-2-ona o 2-tiona derivados, sus metodos de preparacion y su uso terapeutico
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FD Application declared void or lapsed